BradStevenKahlMD

Hematology • Saint Louis, MO

Hematologic Oncology

Professor of Medicine

Join to view full profile

Dr. Kahl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kahl's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Fax+1 314-362-3192

Summary

Dr. Brad Kahl is a hematologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from Tufts University School of Medicine and has been in practice 23 years. He specializes in the treatment of lymphoma and CLL and is experienced in hematologic oncology and benign hematology.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1998 - 2000
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1994 - 1998
Tufts University School of MedicineClass of 1994

Certifications & Licensure

MO State Medical License 2015 - 2025
IL State Medical License 2020 - 2023
WI State Medical License 1995 - 2015
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 23
Completed
Phase 3
Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Completed
Phase 2
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma Start of enrollment: 2007 May 01
Completed
Phase 2
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 2
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma Start of enrollment: 2000 Jun 01
Completed
Phase 2
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance Start of enrollment: 2005 Jan 25
Terminated
Phase 2
R-CHOP + GM-CSF for Previously Untreated LCL in Elderly Start of enrollment: 2002 Mar 01
Completed
Phase 2
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab Start of enrollment: 2010 Dec 06
Completed
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma Start of enrollment: 2012 Feb 06
Completed
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Start of enrollment: 2013 Mar 06
Recruiting
Not Applicable
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Start of enrollment: 2016 Mar 01
Completed
Phase 1
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma Start of enrollment: 2016 Apr 18
Completed
Phase 1
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Start of enrollment: 2018 Nov 29
Active, not recruiting
Phase 2
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2022 Feb 15
Withdrawn
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

52 citations
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Victor M. Orellana-Noia, Daniel R Reed, A. Mccook, Jeremy M Sen, Christian M Barlow
Blood. 2021-09-27
6 citations
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Sarah C Rutherford, Jun Yin, Levi Pederson, Gabriela Perez Burbano, Betsy LaPlant
Journal of Clinical Oncology. 2023-01-10
113 citations
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Simon Rule, Martin Dreyling, Andre Goy, Georg Hess, Rebecca Auer
Haematologica. 2019-05-01

Journal Articles

Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas into Effective New Therapies
Daniel J Landsburg, Brad S Kahl, Clinical Lymphoma, Myeloma, & Leukemia
Ibrutinib for the Treatment of relapsed/refractory Mantle Cell Lymphoma: Extended 3.5-year Follow-up from a Pooled Analysis
Brad Kahl, Andre Goy, Haematologica
CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a ...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0411
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended ...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Brad S. Kahl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect PatientsApril 28th, 2023
Autologous Stem Cell Transplant for Mantle Cell Lymphoma and the Transition Toward the Use of BTK InhibitorsJanuary 31st, 2023
FDA Approves First-in-Class Drug for Follicular LymphomaDecember 23rd, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member